Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

By Harald Hampel, Richard Frank, K. Broich, Stefan J. Teipel, R. Katz, John Hardy, K. Herholz, Arun L. W. Bokde, F. Jessen, Yvonne C. Hoessler and 4 more. Nature reviews. Drug discovery, 2010

659 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/b7d9d7032823d1d24d5730f9403d162a014eff91

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Pharmacology

In Physiology

Citations in the corpus

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. (2012, methodology): “Therefore, patients with MCI with pathologic CSF biomarkers could be selected for clinical trials of new disease-modifying therapies.(5,6) Using this approach, fewer patients with MCI would be needed, and the potential beneficial effects of treatments would be easier to detect in such treatment tria”
Lysosomes as a therapeutic target (2019, background): “The amyloid precursor protein (APP) is cleaved by β and γ secretases into amyloid β peptide (Aβ) fragments, particularly Aβ40 and Aβ42 (ReF. 159 ).”
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease (2014, positive): “These biomarkers include cerebrospinal fluid Aß42, total tau, and phosphorylated tau (ptau) concentrations, positron emission tomography of brain amyloid deposition and glucose metabolism, and brain atrophy on magnetic resonance imaging [4].”
Multi-Method Analysis of MRI Images in Early Diagnostics of Alzheimer's Disease (2011, background): “…intervention, structural MRI biomarkers of AD could also aid the development of new disease-modifying drugs by acting as surrogate markers of disease progression, reduce the number of subjects needed to detect significant drug effect and provide quantitative measures of treatment benefits [12].”
Introduction to Revised Criteria for the Diagnosis of Alzheimer’s Disease: National Institute on Aging and the Alzheimer Association Workgroups (2011, background): “[49] Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J, et al.”
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers (2016, background): “Biomarkers are also used in all modern research diagnostic criteria across the AD clinical spectrum, in therapeutic trials, and by regulatory agencies.(7) Because AD pathology is so frequent in the elderly, AD biomarkers are also commonly used in cognitive aging research.”
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease (2011, neutral): “By contrast, there are several important limitations to current knowledge [22].”
Biochemistry and cell biology of tau protein in neurofibrillary degeneration. (2012, background): “One reason is that Tau is elevated in the cerebrospinal fluid (CSF) at an early stage of AD and therefore serves as a biomarker (Hampel et al. 2010; Blennow et al. 2011).”
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria (2016, methodology): “One study in those at high risk because of APOE ε4 and TOMM40 alleles [2,246].”
The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease (2011, background): “By contrast, there are several important limitations to current knowledge [22].”